Unbound C5a Quantification via Magnetic Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying free human C5a complement protein are prone to overestimation due to the lack of specific antibodies that bind only to C5a, leading to incorrect dosage selection and disease monitoring in treatments like ALXN1007, which has affinity for both C5a and C5.
Innovation Solution
A method involving the removal of human C5 from a sample using C5-specific biotinylated antibodies coupled to magnetic beads, followed by the use of a Gyros Bioaffy 200 CD system with centrifugal force to separate and quantify free C5a using biotinylated anti-C5a capture and AlexaFluor labeled detection antibodies, ensuring accurate measurement by avoiding binding to C5.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If anti-C5a antibodies are used to quantify C5a, then C5a can be detected, but C5 binding causes overestimation of C5a levels
Solution Approach 1:
The patent removes C5 from the sample before performing C5a quantification. This is achieved by incubating the sample with C5-specific biotinylated antibodies coupled to magnetic beads, which selectively bind and extract C5 from the mixture, eliminating the source of measurement interference while preserving C5a for accurate detection.
Solution Approach 2:
The patent performs C5 removal as a preliminary step before C5a measurement. By eliminating C5 interference in advance through magnetic bead-based extraction, the subsequent C5a quantification using anti-C5a antibodies can proceed without overestimation errors, ensuring accurate measurement results.
2Measurement precision
If magnetic bead-based C5 removal is performed, then C5 interference is eliminated, but assay complexity increases
Solution Approach 1:
The patent introduces magnetic beads coupled with C5-specific biotinylated antibodies as an intermediary tool to facilitate C5 removal. These magnetic beads act as a mediator that selectively binds C5 through antibody recognition and allows easy separation via magnetic field, simplifying the removal process while maintaining measurement accuracy.
Solution Approach 2:
The patent replaces traditional mechanical separation methods with magnetic field-based separation. By using magnetic beads instead of conventional centrifugation or filtration approaches, the assay achieves efficient C5 removal with simpler operation and faster processing, reducing overall assay complexity despite adding the magnetic bead component.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a precise and specific quantification of free C5a, reducing the additive effect of C5 binding and improving the accuracy of disease monitoring and dosage selection for treatments targeting C5a.
Implementation Method 1
removing human C5 from the sample; wherein the sample is incubated with C5 specific biotinylated antibody coupled to magnetic beads and wherein the magnetic beads coupled to C5 specific biotinylated antibody bound to human C5 are captured with a magnet
Implementation Method 2
binding biotinylated anti-C5a capture antibody to strepavidin-coated particles; wherein said biotinylated anti-C5a capture antibody is added by capillary action to a Gyros Bioaffy 200 CD comprising columns with the strepavidin-coated particles; wherein said CD is subjected to centrifugal force inside a Gyrolab xPlore or a Gyrolab XP instrument, thus driving the biotinylated anti-C5a capture antibody to the strepavidin-coated particles in the columns
Implementation Method 3
binding biotinylated anti-C5a capture antibody to strepavidin-coated particles; wherein said biotinylated anti-C5a capture antibody is added by capillary action to a Gyros Bioaffy 200 CD comprising columns with the strepavidin-coated particles
Implementation Method 4
detecting the captured free C5a; wherein an AlexaFluor labeled anti-C5a detection antibody is added to the CD by capillary action, wherein said anti-C5a detection antibody binds C5a at a different epitope from the epitope bound by the capture antibody
Data Source
AI summary
A method of quantitating free (unbound) human C5a complement protein (C5a) from a sample comprising: binding biotinylated anti-C5a capture antibody to strepavidin-coated particles; capturing the free (unbound) C5 in the sample; detecting the captured free C5a; and quantitating the captured free C5 using laser-induced fluorescence detection; wherein the method is performed in a Gyros Bioaffy 200 CD in a Gyrolab xPlore or a Gyrolab XP instrument; wherein human C5 is first removed from the sample.